CytomX Therapeutics, Inc. Total Liabilities and Equity
CytomX Therapeutics, Inc. (CTMX) had Total Liabilities and Equity of $381.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $381.23M.
- 2026-03-31: Liabilities and Equity $359.36M.
- 2025-12-31: Liabilities and Equity $151.57M.
- 2025-09-30: Liabilities and Equity $158.25M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $381.23M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $359.36M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $151.57M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $158.25M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $175.06M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $98.50M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $120.53M 10-K · filed 2026-03-16 |
| 2024-09-30 | $138.98M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $159.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $184.69M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $201.79M 10-K · filed 2025-03-06 |
| 2023-09-30 | $221.17M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $209.19M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $234.63M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $260.89M 10-K · filed 2024-03-11 |
| 2022-09-30 | $226.49M 10-K · filed 2023-03-27 |
| 2022-06-30 | $260.09M 10-K · filed 2023-03-27 |
| 2022-03-31 | $296.82M 10-K · filed 2023-03-27 |
| 2021-12-31 | $339.41M 10-K/A · filed 2023-03-27 |
| 2021-09-30 | $371.23M 10-K/A · filed 2023-03-27 |
| 2021-06-30 | $402.44M 10-K/A · filed 2023-03-27 |
| 2021-03-31 | $434.16M 10-K/A · filed 2023-03-27 |
| 2020-12-31 | $358.66M 10-K/A · filed 2023-03-27 |
| 2020-09-30 | $375.18M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $402.48M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $436.66M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $341.28M 10-K · filed 2021-02-24 |
| 2019-09-30 | $372.54M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $405.28M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $444.51M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $457.11M 10-K · filed 2020-02-27 |
| 2018-09-30 | $482.73M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $376.94M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $376.46M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $397.64M 10-K · filed 2019-02-27 |
| 2017-09-30 | $387.04M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $351.86M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $177.88M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $199.13M 10-K · filed 2018-03-07 |
| 2016-09-30 | $192.88M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $206.86M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $191.95M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $197.22M 10-K · filed 2017-03-02 |
| 2015-09-30 | $124.78M 10-Q · filed 2015-11-23 |
| 2014-12-31 | $73.06M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |